Given the lower growth forecast, analysts express concern that should the P/E fall in line with the growth outlook, share price might decline. Investors currently holding onto their stock could face future disappointment.
Issuing new shares has diluted EPS growth, potentially affecting the stocks appeal to investors. Despite improved profits, slower EPS growth due to dilution is worrying. Future company profitability estimates are key.
The market tempers expectations for IDACORP growth despite consistent EPS growth. Warning signs surface in IDACORP's investment analysis. Though its strategy attracted investors thanks to better 5yr returns.
Upgrades •$声网(API.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50 •$argenx SE(ARGX.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278) •$Idacorp(IDA.US)$: Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108) •$杰克仕太平洋(JAKK.US)$: BMO Capital Upgrades to Outperform from Market Perform - PT $21 •$可口可乐凡萨瓶装(KOF.US)$: Barclays Upgrades to Overweight from Equal Wei...
Idacorp股票讨论区
5年来营收、营业利润和净利润都非常稳定的缓慢增长,5年平均净利润增长率4.4%,目前22倍市盈率过高了。
• $声网(API.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $12.50
• $argenx SE(ARGX.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $375 (from $278)
• $Idacorp(IDA.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $110 (from $108)
• $杰克仕太平洋(JAKK.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $21
• $可口可乐凡萨瓶装(KOF.US)$ : Barclays Upgrades to Overweight from Equal Wei...
暂无评论